Be-TeaM: an Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients

In the past decades, the panorama of molecular diagnostics and care of non-small cell lung cancer (NSCLC) has rapidly evolved. The discovery of novel drivers for oncogene addiction has led to the development of additional therapeutic options in first as well as in subsequent lines. This, in turn, has fostered the search for robust and reliable molecular screening methods to support clinicians in prompt decision-making [1,2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research